p62/SQSTM1 as an oncotarget mediates cisplatin resistance through activating RIP1‐NF‐κB pathway in human ovarian cancer cells

Platinum‐based therapeutic strategies have been widely used in ovarian cancer treatment. However, drug resistance has greatly limited therapeutic efficacy. Recently, tolerance to cisplatin has been attributed to other factors unrelated to DNA. p62 (also known as SQSTM1) functions as a multifunctiona...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Xiao‐Yu, Zhang, Yu, Zhang, Juan‐Juan, Zhang, Li‐Chao, Liu, Ya‐Nan, Wu, Yao, Xue, Ya‐Nan, Lu, Sheng‐Yao, Su, Jing, Sun, Lian‐Kun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5497928/
https://www.ncbi.nlm.nih.gov/pubmed/28498503
http://dx.doi.org/10.1111/cas.13276

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5497928/
https://www.ncbi.nlm.nih.gov/pubmed/28498503
http://dx.doi.org/10.1111/cas.13276

Ejemplares similares